{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:49:18Z","timestamp":1792705758386,"version":"4.5.0"},"reference-count":30,"publisher":"Media Sphere Publishing Group","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. nevrol. psikhiatr. im. S.S. Korsakova"],"published-print":{"date-parts":[[2015]]},"DOI":"10.17116\/jnevro20151154183-87","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T16:05:33Z","timestamp":1460649933000},"page":"83","source":"Crossref","is-referenced-by-count":5,"title":["The use of buspirone in clinical practice"],"prefix":"10.17116","volume":"115","author":[{"given":"O. S.","family":"Levin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6743","reference":[{"key":"key-10.17116\/jnevro20151154183-87-1","unstructured":"Goldberg HL. Buspirone \u2014 a new antianxiety agent not chemically related to any presently marketed drugs. Psychopharmacol Bull. 1979;15:90-92."},{"key":"key-10.17116\/jnevro20151154183-87-2","doi-asserted-by":"crossref","unstructured":"Ikram H, Haleem DJ. Attenuation of apomorphine-induced sensitization by buspirone. Pharmacol. Biochem Behav. 2011;99:444-450.","DOI":"10.1016\/j.pbb.2011.04.007"},{"key":"key-10.17116\/jnevro20151154183-87-3","doi-asserted-by":"crossref","unstructured":"Mahmood I, Sahaiwalla C. Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clin Pharmacokinet. 1999;36:277-287.","DOI":"10.2165\/00003088-199936040-00003"},{"key":"key-10.17116\/jnevro20151154183-87-4","unstructured":"DSM-V. Washington: APA. 2013"},{"key":"key-10.17116\/jnevro20151154183-87-5","doi-asserted-by":"crossref","unstructured":"Pecknold JC. A risk-benefit assessment of buspirone in the treatment of anxiety disorders. Drug Saf. 1997;16:118-132.","DOI":"10.2165\/00002018-199716020-00004"},{"key":"key-10.17116\/jnevro20151154183-87-6","doi-asserted-by":"crossref","unstructured":"Sramek JJ, Hong WW, Hamid S, Nape B, Cutler NR. Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety. Depress Anxiety. 1999;9:131-134.","DOI":"10.1002\/(SICI)1520-6394(1999)9:3<131::AID-DA5>3.0.CO;2-H"},{"key":"key-10.17116\/jnevro20151154183-87-7","doi-asserted-by":"crossref","unstructured":"Grady TA, Pigott TA, L\u2019Heureux F. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive \u2014 compulsive disorder. Am J Psychiatry. 1993;150:819-821.","DOI":"10.1176\/ajp.150.5.819"},{"key":"key-10.17116\/jnevro20151154183-87-8","doi-asserted-by":"crossref","unstructured":"Gross MD. Buspirone in ADHD with ODD. J Am Acad Child Adolesc Psychiatry. 1995;34:1260.","DOI":"10.1097\/00004583-199510000-00009"},{"key":"key-10.17116\/jnevro20151154183-87-9","unstructured":"Herrmannm N, Eryavec G. Buspirone in the management of agitation and aggression associated with obsessive compulsive disorder. J Clin Psychiatry. 1991;52:13-14."},{"key":"key-10.17116\/jnevro20151154183-87-10","doi-asserted-by":"crossref","unstructured":"Lee ST, Park JH, Kim M. Efficacy of the 5-HT1A agonist, buspirone hydrochloride, in migraineurs with anxiety: a randomized, prospective, parallel group, double-blind, placebo-controlled study. Headache. 2005;45:1004-1011.","DOI":"10.1111\/j.1526-4610.2005.05181.x"},{"key":"key-10.17116\/jnevro20151154183-87-11","doi-asserted-by":"crossref","unstructured":"van Vliet IM, den Boer JA, Westenberg HG, Pian KL. Clinical effects of buspirone in social phobia: a double-blindplacebo-controlled study. J Clin Psychiatry. 1997;58:164-168.","DOI":"10.4088\/JCP.v58n0405"},{"key":"key-10.17116\/jnevro20151154183-87-12","doi-asserted-by":"crossref","unstructured":"Levy M, Berson A, Cook T. Treatment of agitation following traumatic brain injury: a review of the literature. Neuro Rehabilitation. 2005;20:279-306.","DOI":"10.3233\/NRE-2005-20405"},{"key":"key-10.17116\/jnevro20151154183-87-13","doi-asserted-by":"crossref","unstructured":"Apter JT, Allen LA. Buspirone: future directions. J Clin Psychopharmacol. 1999;19:86-93.","DOI":"10.1097\/00004714-199902000-00014"},{"key":"key-10.17116\/jnevro20151154183-87-14","doi-asserted-by":"crossref","unstructured":"Chamberlain SR, Muller U, Deakin JB. Lack of deleterious effects of buspirone on cognition inhealthy male volunteers. J Psychopharmacol. 2007;21:210-215.","DOI":"10.1177\/0269881107068066"},{"key":"key-10.17116\/jnevro20151154183-87-15","doi-asserted-by":"crossref","unstructured":"Kim S, Fowler J, Skolnick P. Therapeutic doses of buspirone block D3 receptors in the living primate brain. International Journal of Neuropsychopharmacology. 2014;17:1257-1267.","DOI":"10.1017\/S1461145714000194"},{"key":"key-10.17116\/jnevro20151154183-87-16","doi-asserted-by":"crossref","unstructured":"Griffith JD, Jasinski DR, Casten GP, McKinney GR. Investigation of the abuse liability of buspirone inalcohol-dependent patients. Am J Med. 2007;80:30-35.","DOI":"10.1016\/0002-9343(86)90329-3"},{"key":"key-10.17116\/jnevro20151154183-87-17","unstructured":"Cornelius JR, Bukstein O, Salloum I, Clark D. Alcoholand psychiatric comorbidity. Recent Dev Alcohol. 2003;16:361-374."},{"key":"key-10.17116\/jnevro20151154183-87-18","doi-asserted-by":"crossref","unstructured":"Malec E, Malec T, Gagne MA, Dongier M. Buspirone in the treatment of alcohol dependence: a placebo-controlledtrial. Alcohol Clin Exp Res. 1996;20:307-312.","DOI":"10.1111\/j.1530-0277.1996.tb01644.x"},{"key":"key-10.17116\/jnevro20151154183-87-19","unstructured":"Howland RH. Drug therapies for tardive dyskinesia: part 2. J Psychosoc Nurs Ment Health Serv. 2011;49:17-20."},{"key":"key-10.17116\/jnevro20151154183-87-20","doi-asserted-by":"crossref","unstructured":"Haleem DJ, Samad N, Haleem MA. Reversal of haloperidol-induced extrapyramidal symptoms by buspirone:a time-related study. Behav Pharmacol. 2007;18:147-153.","DOI":"10.1097\/FBP.0b013e3280dec67f"},{"key":"key-10.17116\/jnevro20151154183-87-21","doi-asserted-by":"crossref","unstructured":"Bara-Jimenez W, Bibbiani F. Morris, Effects of serotonin 5-HT1A agonist in advanced Parkinson\u2019s disease. Mov Disord. 2005;20:932-936.","DOI":"10.1002\/mds.20370"},{"key":"key-10.17116\/jnevro20151154183-87-22","doi-asserted-by":"crossref","unstructured":"Politis M. Dyskinesias after neural transplantation in Parkinson\u2019s disease: what do we know and what is next? BMC Med. 2010;2:8-80.","DOI":"10.1186\/1741-7015-8-80"},{"key":"key-10.17116\/jnevro20151154183-87-23","doi-asserted-by":"crossref","unstructured":"Kleedorfer B, Lees AJ, Stern GM. Buspirone in the treatment of levodopa induced dyskinesias. J Neurol Neurosurg Psychiatry. 1991;54:376-377.","DOI":"10.1136\/jnnp.54.4.376-a"},{"key":"key-10.17116\/jnevro20151154183-87-24","unstructured":"Shireen E, Haleem DJ. Motor effects of buspirone: relationship with dopamine and serotonin in the striatum. J Coll Physicians Surg Pak. 2005;15:753-756."},{"key":"key-10.17116\/jnevro20151154183-87-25","doi-asserted-by":"crossref","unstructured":"Assadi M, Campellone JV, Janson CG. Treatment of spinocerebellar ataxia withbuspirone. J Neurol Sci. 2007;260:143-146.","DOI":"10.1016\/j.jns.2007.04.019"},{"key":"key-10.17116\/jnevro20151154183-87-26","doi-asserted-by":"crossref","unstructured":"Lou JS, Goldfarb L, McShane L. Use of buspirone for treatment of cerebellar ataxia. An open-label study. Arch Neurol. 1995;52:982-988.","DOI":"10.1001\/archneur.1995.00540340074015"},{"key":"key-10.17116\/jnevro20151154183-87-27","doi-asserted-by":"crossref","unstructured":"Menkes DB. Buspirone augmentation of sertraline. Br J Psychiatry. 1995;166:823-824.","DOI":"10.1192\/S0007125000075292"},{"key":"key-10.17116\/jnevro20151154183-87-28","doi-asserted-by":"crossref","unstructured":"Norden M. Buspirone treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors. Depression. 1994;2:109-112.","DOI":"10.1002\/depr.3050020208"},{"key":"key-10.17116\/jnevro20151154183-87-29","unstructured":"Phillips KA. An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder. Psychopharmacol Bull. 1996;32:175-180."},{"key":"key-10.17116\/jnevro20151154183-87-30","doi-asserted-by":"crossref","unstructured":"van Ameringen M, Mancini C, Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs)in social phobia. J Affect Disord. 1996;39:115-121.","DOI":"10.1016\/0165-0327(96)00030-4"}],"container-title":["Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T17:57:59Z","timestamp":1600451879000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.mediasphera.ru\/issues\/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova\/2015\/4\/downloads\/ru\/071997-729820150414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"alternative-id":["jnevro20151154183-87"],"URL":"https:\/\/doi.org\/10.17116\/jnevro20151154183-87","relation":{},"ISSN":["1997-7298"],"issn-type":[{"value":"1997-7298","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}